KRAS and cancer: Specifically, genes promoting glutamine–glutathione transition, including glutaminase 1, SLC1A5, K-Ras, γ-glutamylcysteine ligase, c-Myc, and NRF2, showed reduced expression, leading to excessive cellular ROS level and enhanced cancer cell apoptosis.